Skip to content

The Effects of Alcohol Consumption on Central Adiposity

The Effects of Alcohol Consumption on Central Adiposity and Testosterone Following Weight Loss in Obese, Pre-menopausal Women

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03521817
Acronym
CONSUME
Enrollment
12
Registered
2018-05-11
Start date
2018-05-18
Completion date
2019-11-04
Last updated
2020-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adiposity, Alcohol Drinking, Obesity, Visceral Obesity, Weight Loss

Brief summary

The objective of the proposed study is to enroll women with obesity that will undergo a controlled, energy restricted feeding intervention to test the effects of chronic ethanol consumption on adipose distribution and circulating testosterone during weight loss.

Detailed description

Alcohol (i.e. ethanol) is one of the most widely used recreational substances by humans and is consumed regularly by much of the U.S. population. Despite the high prevalence of alcohol intake, the metabolic health effects associated with use have not been firmly established. There is a paucity of data from longitudinal studies in humans that examine the metabolic response to routine alcohol consumption in a randomized controlled trial (RCT). This is a novel pilot study to examine, for the first time, the effects of ethanol consumption on fat distribution and testosterone during weight loss in a RCT. Findings from this study would provide insight into an interesting and unanswered question -- does routine alcohol intake exert unfavorable health effects despite the expected beneficial outcomes of caloric restriction and weight loss? This research may provide new knowledge of the metabolic outcomes resulting from alcohol intake and pathways that may be involved leading to potential new therapeutic targets of treatment. The objective of the proposed study is to enroll women with obesity that will undergo a controlled, energy restricted feeding intervention to test the effects of chronic ethanol consumption on adipose distribution and circulating testosterone during weight loss. Women will be randomized to an ethanol-free control group or an ethanol-consuming group, and all will consume 30% energy-restricted diets.

Interventions

OTHERAlcohol

The ethanol group will consume a 30% energy restriction diet that will also include \ 2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol.

This group will not consume alcohol. Thus 0 kcal/d will come from alcohol

Sponsors

Ursula A. White
CollaboratorUNKNOWN
Frank L. Greenway
CollaboratorUNKNOWN
Martin, Corby, K., M.D.
CollaboratorINDIV
Pennington Biomedical Research Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

This is a between-subjects parallel study design. All women will undergo a 30% energy restriction for 8-weeks and will be randomized to an ethanol-consuming group or a non-ethanol control group at the start of the study.

Eligibility

Sex/Gender
FEMALE
Age
21 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* \- Pre-menopausal women only * 21-40 years of age * BMI 27-50 kg/m2 (+/- 0.5 will be accepted) * Must practice and be willing to continue to practice appropriate birth control (defined as a method which results in a low failure rate, i.e., less than 1% per year, when used consistently and correctly, such as double barrier methods \[male condom with spermicide, with or without cervical cap or diaphragm\], implants, intrauterine contraceptive devices, tubal ligation (surgically sterile), abstinence, or in an established relationship with a vasectomized or same sex partner) during the entire duration of the study * Must be willing to adhere to all study procedures, including consumption of all study foods and beverages and attendance at all study visits * \- Must be willing to eat at least one meal at PBRC 3 times per week on weekdays (excluding holidays) * Must be willing to consume alcohol * Must be willing to abstain from alcohol for 8-weeks if randomized to non-alcohol control group. * Must be a daily, or almost daily drinker, defined as typically consuming at least 8 drinks per week, but no more than 4 per day * Must be willing to undergo an overnight alcohol test (at home) of ethanol at the proposed dose before enrollment in the study * Must have access to a device that can be used for video monitoring of compliance (i.e. Skype) * Must be willing to have your blood stored for future research

Exclusion criteria

* \- Non-drinkers of alcohol * Habitual binge drinkers, as defined by the consumption of ≥ 4 standard drinks per day or ≥ 28 drinks per week. * Self-reported alcoholics or a history of alcoholism * Have a 1st degree relative with alcoholism * Any attendance or inpatient stay for alcohol or drug treatment * Display any characteristics of current or future substance abuse disorders * Presence of any psychiatric, behavioral, or medical disorder that, in the opinion of the PIs, Co-I, or MI, may interfere with study participation, the ability to adhere to the protocol, or has the potential for increased substance abuse * Prescription medications that interact with alcohol intake * Abnormal screening laboratory safety tests * Smokers * Diagnosis of Type 1 or 2 diabetes mellitus, cancer, or major organ disease * Serious digestive disorders * Conditions that affect metabolism or body weight (i.e. uncontrolled thyroid conditions, bariatric surgery, pregnancy, breastfeeding) * Partial and/or full hysterectomy * Hormonal pharmaceutical contraceptives including oral contraception (birth control pills), injectables (Depo-Provera), or the patch (Xulane) * PCOS * Use of medications that affect body weight or metabolism (i.e. atypical antipsychotics, weight loss medications). * Not willing to store biospecimens for future use

Design outcomes

Primary

MeasureTime frameDescription
Change in Central (Abdominal) Adiposity8 weekschange in visceral abdominal adipose tissue from baseline to post intervention

Countries

United States

Participant flow

Participants by arm

ArmCount
Alcohol
Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat; (minus the \ 240 kcals from ethanol). The Etoh group will consume a 30% energy restriction diet that will also include \ 2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). Alcohol: The ethanol group will consume a 30% energy restriction diet that will also include \ 2.5 standard drinks, or 35 grams of ethanol, administered as 80-proof distilled spirits (e.g. 80 proof gin, rum, vodka, whiskey, or tequila). In the United States, one standard drink contains roughly 14 grams of pure alcohol.
7
No Alcohol
No Etoh will have a 30% reduction in calories from weight maintenance and will consume the same percentage of each traditional macronutrient (20% protein, 50% carbohydrate, and 30% fat). No Alcohol: This group will not consume alcohol. Thus 0 kcal/d will come from alcohol
5
Total12

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyProtocol Violation01

Baseline characteristics

CharacteristicAlcoholNo AlcoholTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
7 Participants5 Participants12 Participants
Age, Continuous32 years
STANDARD_DEVIATION 9
31 years
STANDARD_DEVIATION 7
32 years
STANDARD_DEVIATION 8
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
2 Participants1 Participants3 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants0 Participants1 Participants
Race (NIH/OMB)
White
4 Participants4 Participants8 Participants
Sex: Female, Male
Female
7 Participants5 Participants12 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 5
other
Total, other adverse events
1 / 72 / 5
serious
Total, serious adverse events
0 / 70 / 5

Outcome results

Primary

Change in Central (Abdominal) Adiposity

change in visceral abdominal adipose tissue from baseline to post intervention

Time frame: 8 weeks

ArmMeasureValue (MEAN)Dispersion
AlcoholChange in Central (Abdominal) Adiposity-0.250 kgStandard Error 0.115
No AlcoholChange in Central (Abdominal) Adiposity-0.071 kgStandard Error 0.075
p-value: <0.231t-test, 2 sided

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026